186 related articles for article (PubMed ID: 26044359)
1. Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
Gao C; Grøtli M; Eriksson LA
J Mol Model; 2015 Jul; 21(7):167. PubMed ID: 26044359
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
Yang Y; Shen Y; Liu H; Yao X
J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
[TBL] [Abstract][Full Text] [Related]
3. High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
Dunna NR; Kandula V; Girdhar A; Pudutha A; Hussain T; Bandaru S; Nayarisseri A
Asian Pac J Cancer Prev; 2015; 16(16):7089-95. PubMed ID: 26514495
[TBL] [Abstract][Full Text] [Related]
4. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
Dietrich J; Hulme C; Hurley LH
Bioorg Med Chem; 2010 Aug; 18(15):5738-48. PubMed ID: 20621496
[TBL] [Abstract][Full Text] [Related]
5. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
Namboodiri HV; Bukhtiyarova M; Ramcharan J; Karpusas M; Lee Y; Springman EB
Biochemistry; 2010 May; 49(17):3611-8. PubMed ID: 20337484
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.
Moccia M; Liu Q; Guida T; Federico G; Brescia A; Zhao Z; Choi HG; Deng X; Tan L; Wang J; Billaud M; Gray NS; Carlomagno F; Santoro M
PLoS One; 2015; 10(6):e0128364. PubMed ID: 26046350
[TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
[TBL] [Abstract][Full Text] [Related]
8. Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation.
Wang Y; Peng C; Wang G; Xu Z; Luo Y; Wang J; Zhu W
Chem Biol Drug Des; 2019 May; 93(5):934-948. PubMed ID: 30689282
[TBL] [Abstract][Full Text] [Related]
9. Studies of N(9)-arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations.
Ma S; Zeng G; Fang D; Wang J; Wu W; Xie W; Tan S; Zheng K
Mol Biosyst; 2015 Feb; 11(2):394-406. PubMed ID: 25406390
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.
Plaza-Menacho I; Mologni L; Sala E; Gambacorti-Passerini C; Magee AI; Links TP; Hofstra RM; Barford D; Isacke CM
J Biol Chem; 2007 Oct; 282(40):29230-40. PubMed ID: 17664273
[TBL] [Abstract][Full Text] [Related]
11. Discovery of
Mologni L; Dalla Via M; Chilin A; Palumbo M; Marzaro G
ChemMedChem; 2017 Aug; 12(16):1390-1398. PubMed ID: 28639308
[TBL] [Abstract][Full Text] [Related]
12. In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach.
George Priya Doss C; Rajith B; Chakraboty C; Balaji V; Magesh R; Gowthami B; Menon S; Swati M; Trivedi M; Paul J; Vasan R; Das M
Mol Biosyst; 2014 Mar; 10(3):421-36. PubMed ID: 24336963
[TBL] [Abstract][Full Text] [Related]
13. Design and development of photoswitchable DFG-Out RET kinase inhibitors.
Xu Y; Gao C; Andreasson M; Håversen L; Carrasco MP; Fleming C; Lundbäck T; Andréasson J; Grøtli M
Eur J Med Chem; 2022 Apr; 234():114226. PubMed ID: 35305461
[TBL] [Abstract][Full Text] [Related]
14. Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, 'DFG-out' inhibitors.
Modi SJ; Kulkarni VM
J Biomol Struct Dyn; 2022 Aug; 40(12):5712-5727. PubMed ID: 33459187
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
16. Molecular Modelling Studies on Pyrazole Derivatives for the Design of Potent Rearranged during Transfection Kinase Inhibitors.
Bhujbal SP; Keretsu S; Cho SJ
Molecules; 2021 Jan; 26(3):. PubMed ID: 33525725
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
Terzyan SS; Shen T; Liu X; Huang Q; Teng P; Zhou M; Hilberg F; Cai J; Mooers BHM; Wu J
J Biol Chem; 2019 Jul; 294(27):10428-10437. PubMed ID: 31118272
[TBL] [Abstract][Full Text] [Related]
18. Developing Dynamic Structure-Based Pharmacophore and ML-Trained QSAR Models for the Discovery of Novel Resistance-Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI Analysis.
Sayyah E; Oktay L; Tunc H; Durdagi S
ChemMedChem; 2024 Jun; 19(12):e202300644. PubMed ID: 38523069
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.
Wang C; Liu H; Song Z; Ji Y; Xing L; Peng X; Wang X; Ai J; Geng M; Zhang A
Bioorg Med Chem Lett; 2017 Jun; 27(11):2544-2548. PubMed ID: 28404375
[TBL] [Abstract][Full Text] [Related]
20. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
Zhang Q; Zhang X; You Q
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
